Key Insights The projected fair value for Climb Bio is US$9.09 based on 2 Stage Free Cash Flow to Equity Climb ...
What Genmab’s latest trial data and royalty update mean for shareholders Genmab (CPSE:GMAB) has drawn fresh attention after releasing Phase 3 EPCORE DLBCL-1 topline data for epcoritamab and reporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results